The Proteomics Center at Medicon Village is focused on advanced analysis of the human proteome, using a wide range of cutting-edge technologies, highly qualified personnel and advanced bioinformatics. A unique proteomic workflow has been created within the center enabling a rapid automated processing of vast amounts of data. Based on this approach the Proteomic Center has performed the largest tumor protein analysis reported so far on 600 breast tumors, 200 oesophageal tumors and over 100 ovarian tumors.
Furthermore, in-depth analysis have been performed resulting in the unique Breast Cancer Index based on >13 million mass spectrometry (MS) spectra and covering over 13.000 proteins expressed in breast cancer. In addition, the Breast Cancer Atlas describes the cellular location of all the indexed proteins. Consequently, proteomics has demonstrated a tremendous potential to impact the way we understand complex biological systems such as human cancer, and how we can prognosticate this multifaceted disease.
The proteomic center has recently established a collaboration with the Rogosin Institute in New York. The Rogosin Institute has developed novel approaches that inhibits cancer growth. The exact mechanism of this inhibition is not known and the Rogosin Institute has identified the Proteomics Center at Medicon Village as the leading expert to unravel the observed growth regulation of cancer cells, which could have implications for future treatments strategies.